Last reviewed · How we verify
NCT05238012: XTREME
Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes
Phase 4 trial testing Xuezhikang Capsule in Metabolism Disorder, Lipid in 392 participants. Completed in 2 April 2024.
2 April 2024
Quick facts
| Lead sponsor | Heart Health Research Center |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 392 |
| Start date | 2 August 2022 |
| Primary completion | 2 April 2024 |
| Estimated completion | 2 April 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Xuezhikang Capsule — full drug profile →
- Atorvastatin Calcium Tablets — full drug profile →
Conditions studied
- Metabolism Disorder, Lipid — all drugs for Metabolism Disorder, Lipid →
- Metabolism Disorder, Glucose — all drugs for Metabolism Disorder, Glucose →
Sponsor
Heart Health Research Center
Who can join
40 and older, any sex, with Metabolism Disorder, Lipid or Metabolism Disorder, Glucose. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a prospective, randomized, open-label, multi-center trial. The primary objective of the study is to assess whether XZK 1200mg/d, compared to atorvastatin 20mg/d, has a favorable impact on HbA1c levels at 24 weeks of treatment in dyslipidemia patients with prediabetes
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05238012
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metabolism Disorder, Lipid
Currently open trials in the same condition.
- NCT06336070 — Metabolic Flexibility and Autonomic Control After Muscle Power vs Metabolic Power Training in Postmenopausal Oncological · NA · recruiting
- NCT03669809 — The Biological Rhythm of Human Metabolite · recruiting
Other Heart Health Research Center trials
Trials by the same sponsor.
- NCT07194785 — AI-Assisted Smart Stethoscope Screening for Structural Heart Disease in School Students in Ruyang County · completed
- NCT06764225 — Effects of Low-Sodium Salt on Death, HF Hospitalization/ Emergency Department Visits and Quality of Life in HF Patients · NA · recruiting
- NCT06455878 — Mobile Applet for Weight Management in Obese Heart Failure Patients · NA · recruiting
- NCT06427096 — Effect of Healthy Family Program on Population Blood Pressure · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05238012 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Heart Health Research Center
- Last refreshed: 21 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05238012.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing